Pranlukast, a Cysteinyl Leukotriene Antagonist, Reduces Serum Eosinophil Cationic Protein Levels in Patients with Asthma
Hiroshima Journal of Medical Sciences 48 巻 4 号
105-110 頁
1999-12 発行
アクセス数 : 1072 件
ダウンロード数 : 142 件
今月のアクセス数 : 2 件
今月のダウンロード数 : 1 件
この文献の参照には次のURLをご利用ください : https://ir.lib.hiroshima-u.ac.jp/00037739
| ファイル情報(添付) | |
| タイトル ( eng ) |
Pranlukast, a Cysteinyl Leukotriene Antagonist, Reduces Serum Eosinophil Cationic Protein Levels in Patients with Asthma
|
| 作成者 |
Ishioka Shinichi
Hozawa Soichiro
Hiyama Keiko
Maeda Akihiro
Yamakido Michio
|
| 収録物名 |
Hiroshima Journal of Medical Sciences
|
| 巻 | 48 |
| 号 | 4 |
| 開始ページ | 105 |
| 終了ページ | 110 |
| 収録物識別子 |
[PISSN] 0018-2052
[EISSN] 2433-7668
[NCID] AA00664312
|
| 抄録 |
Cysteinyl leukotrienes (cysLTs) are considered to be important mediators involved in bronchial asthma and the ensuing eosinophilic inflammation. We evaluated the effects of pranlukast, a potent and selective cysLT receptor antagonist, on the clinical course and serum eosinophil cationic protein (ECP) levels of 10 asthmatic patients. A four-week administration of pranlukast increased the morning peak expiratory flow (PEF) (p=0.007) and decreased as-needed /3z-agonist use (p=0.021). Changes in the morning PEF inversely correlated with those in the serum ECP levels (r=－0.80, p=0.0057). These results suggest that cysLTs are important mediators involved in eosinophilic inflammation, a major pathophysiologic feature of bronchial asthma in humans.
|
| 著者キーワード |
Bronchial asthma
Cysteinyl leukotriene receptor antagonist
Pranlukast
Serum eosinophil cationic protein
|
| 内容記述 |
Part of this study was supported by a research grant from the Japanese Ministry of Health and Welfare.
|
| NDC分類 |
医学 [ 490 ]
|
| 言語 |
英語
|
| 資源タイプ | 紀要論文 |
| 出版者 |
Hiroshima University Medical Press
|
| 発行日 | 1999-12 |
| 出版タイプ | Version of Record（出版社版。早期公開を含む） |
| アクセス権 | オープンアクセス |
| 収録物識別子 |
[ISSN] 0018-2052
[NCID] AA00664312
|
